Sunday, October 25, 2015

How Turing’s Controversial $750 Pill Could be Eclipsed by a $1 Rival

Democratic presidential frontrunner Hillary Clinton called him an outrageous drug “price gouger.” GOP frontrunner Donald Trump dismissed him as “a spoiled brat.” And Sen. Bernie Sanders rejected his campaign contribution as soiled money.

Martin Shkreli, the cocky, 32-year-old former Wall Street hedge fund manager and owner of Turing Pharmaceuticals, caused a national furor recently after he acquired the rights to a drug called Daraprim for treating parasitic infections and then jacked up the price by 5,000 percent – from $13.50 a tablet to $750.


Related: The Feds Finally Make a Move on Soaring Drug Prices


The drug has been on the market for more than 60 years, and the Infectious Disease Society of America and others have estimated that it would cost $336,000 a year to treat someone with toxoplasmosis at $750 per pill, according to reports.



Read More Here

No comments:

Post a Comment

Hello and thank you for visiting my blog. Please share your thoughts and leave a comment :)